{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:53:30Z","timestamp":1781783610466,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-109-2623-E-002-004-NU"],"award-info":[{"award-number":["MOST-109-2623-E-002-004-NU"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-111-2623-E-002-003-NU"],"award-info":[{"award-number":["MOST-111-2623-E-002-003-NU"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-111-3111-Y-042A-009"],"award-info":[{"award-number":["MOST-111-3111-Y-042A-009"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["109-013"],"award-info":[{"award-number":["109-013"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113668","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:43:51Z","timestamp":1662684231000},"page":"113668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer"],"prefix":"10.1016","volume":"155","author":[{"given":"Ming-Cheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Fang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Cheng","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2022.113668_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3802\/jgo.2013.24.4.342","article-title":"Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan","volume":"24","author":"Chiang","year":"2013","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113668_bib2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.biopha.2022.113668_bib3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2022.113668_bib4","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0090-8258(03)00472-4","article-title":"First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer","volume":"90","author":"Stuart","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2022.113668_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10080266","article-title":"Targeting the microenvironment in high grade serous ovarian cancer","volume":"10","author":"Nwani","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.113668_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1536012120939398","article-title":"Two patient studies of a companion diagnostic immuno-positron emission tomography (PET) tracer for measuring human CA6 expression in cancer for antibody drug conjugate (ADC) therapy","volume":"19","author":"Natarajan","year":"2020","journal-title":"Mol. Imaging"},{"issue":"1","key":"10.1016\/j.biopha.2022.113668_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/GCO.0000000000000596","article-title":"Biomarkers that may predict response to immunotherapy in ovarian malignancies","volume":"32","author":"Chin","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113668_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2022.113668_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0960327119891218","article-title":"Chitinase-like protein YKL-40 regulates human bronchial epithelial cells proliferation, apoptosis, and migration through TGF-beta1\/Smads pathway","volume":"39","author":"Guan","year":"2020","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.biopha.2022.113668_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","article-title":"Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury","volume":"73","author":"Lee","year":"2011","journal-title":"Annu. Rev. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113668_bib11","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1177\/147323001003800427","article-title":"YKL-40 protein levels and clinical outcome of human endometrial cancer","volume":"38","author":"Peng","year":"2010","journal-title":"J. Int. Med. Res."},{"issue":"12","key":"10.1016\/j.biopha.2022.113668_bib12","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.humpath.2009.07.005","article-title":"Overexpression of YKL-40 is an independent prognostic marker in gastric cancer","volume":"40","author":"Bi","year":"2009","journal-title":"Hum. Pathol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113668_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.prp.2011.06.008","article-title":"Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers","volume":"207","author":"Stawerski","year":"2011","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.biopha.2022.113668_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7819-5-17","article-title":"Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer","volume":"5","author":"Kim","year":"2007","journal-title":"World J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113668_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/03009742.2017.1376107","volume":"47","author":"Brahe","year":"2018","journal-title":"Scand. J. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113668_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1189\/jlb.3VMR0415-142R","article-title":"YKL-40\/CHI3L1 drives inflammation on the road of tumor progression","volume":"98","author":"Libreros","year":"2015","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113668_bib17","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-10-0868","article-title":"A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers","volume":"10","author":"Faibish","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2022.113668_bib18","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ab9510","article-title":"Liposomal dexamethasone-moxifloxacin nanoparticle combinations with collagen\/gelatin\/alginate hydrogel for corneal infection treatment and wound healing","volume":"15","author":"Chang","year":"2020","journal-title":"Biomed. Mater."},{"issue":"6","key":"10.1016\/j.biopha.2022.113668_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/1933719114557893","article-title":"Establishment of a new ovarian cancer cell line CA5171","volume":"22","author":"Chiang","year":"2015","journal-title":"Reprod. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2022.113668_bib20","doi-asserted-by":"crossref","first-page":"15332","DOI":"10.1074\/jbc.M110.212514","article-title":"Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma","volume":"286","author":"Francescone","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2022.113668_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/ERC-18-0300","article-title":"CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells","volume":"26","author":"Lin","year":"2019","journal-title":"Endocr. -Relat. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2022.113668_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4049\/jimmunol.1201827","article-title":"YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-\u03baB pathways, causing bronchial smooth muscle proliferation and migration","volume":"190","author":"Tang","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.113668_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-0716-0247-8_10","article-title":"Interleukin-8 induces proliferation of ovarian cancer cells in 3D spheroids","volume":"2108","author":"Uddin","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113668_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cyto.2012.04.013","article-title":"Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion","volume":"59","author":"Wang","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2022.113668_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2021.08.004","article-title":"A novel (111)indium-labeled dual carbonic anhydrase 9-targeted probe as a potential SPECT imaging radiotracer for detection of hypoxic colorectal cancer cells","volume":"168","author":"Guan","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"18","key":"10.1016\/j.biopha.2022.113668_bib26","doi-asserted-by":"crossref","first-page":"16601","DOI":"10.18632\/oncotarget.3968","article-title":"111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma","volume":"6","author":"Shih","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2022.113668_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/IGC.0000000000000798","article-title":"The prognostic value of plasma YKL-40 in patients with chemotherapy-resistant ovarian cancer treated with bevacizumab","volume":"26","author":"Boisen","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"37","key":"10.1016\/j.biopha.2022.113668_bib28","doi-asserted-by":"crossref","first-page":"39740","DOI":"10.18632\/oncotarget.5469","article-title":"Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma","volume":"6","author":"Chiang","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.biopha.2022.113668_bib29","first-page":"4423","article-title":"High levels of serum HER-2\/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer","volume":"9","author":"Jensen","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2022.113668_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096384","article-title":"Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2022.113668_bib31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2008.18.8367","article-title":"Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population","volume":"27","author":"Johansen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113668_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2018.04.040","article-title":"Differential regulation of the pro-inflammatory biomarker, YKL-40\/CHI3L1, by PTEN\/Phosphoinositide 3-kinase and JAK2\/STAT3 pathways in glioblastoma","volume":"429","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.biopha.2022.113668_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/HP.0000000000001000","article-title":"Radiopharmaceutical therapy","volume":"116","author":"Sgouros","year":"2019","journal-title":"Health Phys."},{"issue":"2","key":"10.1016\/j.biopha.2022.113668_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/02841860310004959","article-title":"Cancer society investigation, biological response to radiation therapy","volume":"42","author":"Turesson","year":"2003","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113668_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nucmedbio.2007.01.004","article-title":"In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer","volume":"34","author":"Sabbah","year":"2007","journal-title":"Nucl. Med. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2022.113668_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1039\/b309961j","article-title":"The role of coordination chemistry in the development of target-specific radiopharmaceuticals","volume":"33","author":"Liu","year":"2004","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2022.113668_bib37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/carcin\/bgt380","article-title":"Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma","volume":"35","author":"Shao","year":"2014","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.biopha.2022.113668_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/PPO.0b013e31813ffd7b","article-title":"High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer","volume":"13","author":"Sura","year":"2007","journal-title":"Cancer J."},{"issue":"8","key":"10.1016\/j.biopha.2022.113668_bib39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/07357907.2012.700987","article-title":"The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas","volume":"30","author":"Balmanoukian","year":"2012","journal-title":"Cancer Investig."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:26:24Z","timestamp":1781781984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222010575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"alternative-id":["S0753332222010575"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113668","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113668"}}